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Abstract
Purpose—This study was designed to examine choroidal thickness in patients with diabetes
using spectral-domain optical coherence tomography.
Methods—Forty-nine patients (49 eyes) with diabetes and 24 age-matched normal subjects
underwent high-definition raster scanning using spectral-domain optical coherence tomography
with frame enhancement software. Patients with diabetes were classified into 3 groups: 11 patients
with mild or moderate nonproliferative diabetic retinopathy and no macular edema, 18 patients
with nonproliferative diabetic retinopathy and diabetic macular edema, and 20 patients with
treated proliferative diabetic retinopathy and no diabetic macular edema (treated proliferative
diabetic retinopathy). Choroidal thickness was measured from the posterior edge of the retinal
pigment epithelium to the choroid/sclera junction at 500-μm intervals up to 2,500 μm temporal
and nasal to the fovea.
Results—Reliable measurements of choroidal thickness were obtainable in 75.3% of eyes
examined. Mean choroidal thickness showed a pattern of thinnest choroid nasally, thickening in
the subfoveal region, and thinning again temporally in normal subjects and patients with diabetes.
Mean subfoveal choroidal thickness was thinner in patients with diabetic macular edema (63.3
μm, 27.2%, P < 0.05) or treated proliferative diabetic retinopathy (69.6 μm, 30.0%, P < 0.01),
compared with normal subjects. There was no difference between nonproliferative diabetic
retinopathy and normal subjects.
Conclusion—Choroidal thickness is altered in diabetes and may be related to the severity of
retinopathy. Presence of diabetic macular edema is associated with a significant decrease in the
choroidal thickness.
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Diabetic retinopathy is a leading cause of vision loss worldwide.1 The development of
macular edema and proliferative retinopathy are major causes of visual impairment.1,2
Clinical and experimental findings suggested that choroidal vasculopathy in diabetes may
play a role in the pathogenesis of diabetic retinopathy.3–5
Various choroidal abnormalities including obstruction of the choriocapillaris, vascular
degeneration, choroidal aneurysms, and choroidal neovascularization have been reported in
histopathologic studies of diabetic eyes.3,6,7 In addition, McLeod and Lutty8 observed a loss
of alkaline phosphatase activity in the diabetic choriocapillaris that represents loss of viable
endothelial cells and concurrent degeneration of the choriocapillaris.
There are few clinical studies on choroidal angiopathy in diabetes. This is because of the
difficulty of imaging the choroid in vivo. Indocyanine green angiography reveals both
hyper- and hypofluorescent spots in diabetic eyes, although the significance is unknown.4,9
It has been proposed that the hypofluorescent spots result from ischemic changes of the
choroidal vessels and represent either a dye filling delay or a defect of the
choriocapillaris.7,10 It is further postulated that the hyperfluorescent spots may be secondary
to the presence of choroidal neovascularization, intra-choroidal microvasculature
abnormalities, or nodules at the level of the choriocapillaris or underlying stroma.4–6,9
Concurrently, Shiragami et al5 described risk factors associated with diabetic choroidopathy
including the presence of severe diabetic retinopathy, poor glycemic control, and the nature
of the treatment regimen.
Additionally, studies assessing the choroidal blood flow beneath the fovea with the use of
laser Doppler flowmetry indicate a reduction of choroidal blood flow and volume in patients
with nonproliferative11 and proliferative diabetic retinopathy. There was a more prominent
decrease in flow in the case of proliferative diabetic retinopathy.12
A better clinical understanding of choroidal damage might be important for an accurate
assessment of diabetic eye disease, but adequate visualization of the choroid using optical
coherence tomography (OCT) has not been possible until recently, owing to its posterior
location and the presence of pigmented cells that attenuate the incident light. Recent reports
showed successful examination and measurement of choroidal thickness in normal and
pathologic states using the Heidelberg Spectralis (Heidelberg Engineering, Heidelberg,
Germany) and Cirrus HD-OCT (Carl Zeiss Meditec Inc, Dublin, CA) spectral-domain OCT
instruments.13–17 The present study was designed to determine if CT is abnormal in patients
with various stages of diabetic retinopathy.
Methods
Subjects
A retrospective analysis was performed on 49 eyes of 49 Type 2 diabetic patients and 24
eyes of 24 normal patients, who underwent high-definition 1-line raster scanning using SD
Cirrus HD-OCT at the New England Eye Center, Tufts Medical Center, Boston, MA,
between December 2009 and June 2010. The normal subjects had normal visual acuity and
did not have any retinal or choroidal pathology on ophthalmoscopy.
The patients with diabetes were classified into 3 groups, according to the Early Treatment
Diabetic Retinopathy Study criteria: 11 patients (11 eyes) with mild or moderate
nonproliferative diabetic retinopathy (NPDR) and no macular edema (NPDR group), 18
patients (18 eyes) with mild or moderate NPDR and diabetic macular edema (DME) (DME
group), and 20 patients (20 eyes) with treated proliferative diabetic retinopathy (PDR)
(treated PDR group). Clinically significant macular edema was assessed by clinical
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examination and spectral-domain OCT imaging, and it was diagnosed based on the presence
or absence of macular thickening or hard exudates at or within 500 μm of the central
macula, as defined by the Early Treatment Diabetic Retinopathy Study protocol.18,19 All
patients with PDR were treated previously with panretinal photocoagulation and did not
demonstrate active retinal neovascularization. Major exclusion criteria included the
following: (1) another ocular diseases (2) previous treatment for DME within 6 months of
scanning, and (3) previous pars plana vitrectomy. Patients were excluded if the hypertension
was uncontrolled or if they had a history of pancreatic transplant or chronic renal failure
requiring dialysis or kidney transplant.
Choroidal Thickness Measurement
The scan pattern used on Cirrus HD-OCT was HD 1-line raster. It is a 6-mm line consisting
of 4,096 A-scans. Images were taken with the vitreoretinal interface adjacent to the zero-
delay and were not inverted to bring the choroid adjacent to zero-delay as image inversion
using the Cirrus software results in a low-quality image. The HD 1-line raster has 20 B-
scans averaged together without tracking. To be included in this study, images had to be at
least 6 of 10 in intensity and taken as close to the fovea as possible, by choosing to image
the thinnest point of the macula, with the understanding that slight differences in positioning
could affect the measured thicknesses. Using the Cirrus linear measurement tool, 2
independent observers measured CT perpendicularly from the outer edge of the
hyperreflective retinal pigment epithelium (RPE) to the inner sclera at 500-μm intervals
temporal and nasal from the fovea, up to 2,500 μm. Furthermore, the central foveal
thickness was also measured at this time to determine the correlation between retinal
thickness and CT.
Statistical Analysis
Data are expressed as means ± standard error of the mean. Statistical analyses were
performed using one-way analysis of variance followed by posttest comparison with Tukey
multiple test. Pearson correlation coefficient was used to evaluate the correlation between
the CTs and central foveal thickness. A 95% confidence interval and a 5% level of
significance were adopted; therefore, the results with a P value ≦0.05 were considered
significant. All statistics were calculated using Graph Pad Prism 5.0 software for Windows.
Results
Table 1 shows the characteristics of diabetic patients and normal subjects. No significant
difference in age was observed between the 4 groups (P = 0.958). The patient percentage in
use of insulin was higher in treated PDR group, compared with NPDR and DME.
Reliable measurements of CT were obtainable in 75.3% of the diabetic patients (49 of 65
patients). Mean CT at each location was plotted (Figure 1). There was a statistically
significant difference between CT of normal subjects and DME group (P < 0.001) and
treated PDR group (P < 0.001). No significant difference between normal subjects and the
NPDR group was observed (P > 0.05). Between DME and treated PDR groups, there was no
significant difference (P > 0.05). Representative images are shown in Figure 2.
Table 2 shows the average CT in each location. The choroid was noted to be thinnest
nasally, thicker in the subfoveal region, and then thinner again temporally (however, not as
thin as the choroid proximal to the disk). This pattern was observed in all groups, and it was
in agreement with previous studies of CT in normal eyes.13,17,20,21
The subfoveal CT was noted to be thinner in patients with diabetic macular edema (63.3
μm, 27.2%, P < 0.05) or treated PDR (69.6 μm, 30.0%, P < 0.01), compared with normal
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subjects (Figure 3). No significant difference between normal and NPDR group was
observed (10.3 μm, 4.5%, P > 0.05).
The correlation between central foveal thickness of the retina and central foveal CT was also
examined. No statistically correlation between 2 measurements was found in NPDR group (r
= 0.016, P = 0.36) and treated PDR group (r = −0.176, P = 0.25), suggesting that retinal
thickness may not be directly related to CT in these groups. In DME patients, a weak
negative correlation was observed (r = −0.4061, P = 0.12) indicating that the central retinal
thickness increases as the CT decreases.
Discussion
A structurally and functionally normal choroidal vasculature is essential for function of the
retina: abnormal choroidal blood volume and/or compromised flow can result in
photoreceptor dysfunction and death.6 The possible role of choroidal vessels in the
pathophysiology of diabetic changes in the retina has been evaluated by histologic
examination. The pathologic findings included increased tortuosity of the blood vessels,
focal vascular dilatation and narrowing, hypercellularity, vascular loops and microaneurysm
formation, areas of nonperfusion, and sinuslike structure formation between the choroidal
lobules.3,22
Until recently, information regarding CT was based primarily on histologic examinations,
which do not necessarily reflect the measurements of this dynamic tissue in vivo.23 Recent
studies demonstrate the potential to image choroidal structure using commercially available
spectral-domain OCT instruments, the Heidelberg Spectralis and Cirrus HD-OCT.15,17 In
this investigation, SD Cirrus HD-OCT was used with light source centered on 800-nm
wavelength, achieving 5-μm axial resolution in tissue. Previously, the full thickness of the
choroid could not be seen in most eyes because of scattering and insufficient light
penetration beyond the retinal pigment epithelium, and signal strength roll-off distal to the
zero-delay line. Decreased signal strength posterior to the retinal pigment epithelium is
compensated by the image enhancement software, which enables visualization of the border
where choroidal tissue meets sclera and allows CT measurements to be performed. With the
enhanced images, reliable measurements of CT were obtainable in 75.3%. The results of this
study were very similar to those reported previously.17,20 When considering in which
patients it was difficult to visualize the choroid/sclera junction, the most frequent group
where this was the case was patients with DME, because of attenuation of the incident light
beam by the intraretinal fluid.
Further, previous investigations reported selective filling of the choriocapillaris during
indocyanine green angiography and choroidal blood flow decrease during laser Doppler
flowmetry in association with non-proliferative diabetic retinopathy. Such findings indicate
that there may be diabetic choroidopathy before the onset of diabetic retinopathy in a subset
of patients.4,11 In our study, significant thinning of the subfoveal choroid was not observed
when comparing patients with NPDR and age-matched normals. One explanation for this
incongruity is that the above-mentioned findings may be focal and involve mainly the
choriocapillaris. Because of resolution limitations of the OCT system used, the
choriocapillaris cannot be reliably identified. Further development of OCT technology
would likely prove valuable in the investigation of diabetic choroidopathy.
The present study showed a significant decrease in CT in patients with DME and treated
PDR, compared with normal subjects. We can speculate that the thinner choroid may
indicate an overall reduction of choroidal blood flow in patients with DME and more
prominent in patients with treated PDR, as was previously demonstrated with laser Doppler
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flowmetry and indocyanine green angiography.5,11,12 Therefore, it is likely that the
decreased CT may be related to retinal tissue hypoxia, as the choroid is the major source of
nutrition for the RPE and outer retinal layers. What is not clear is whether the thinning
detected is primary or secondary to overlying retinal ischemia.
Untreated systemic hypertension is associated with choroidopathy, which occurs later than
the retinal vascular changes of arteriolar narrowing and arterio-venous crossing changes.24
Although some patients enrolled in this study presented systemic hypertension, it should not
interfere in CT because the hypertension was controlled.
This retrospective study has some limitations. Patients with diabetes and no diabetic
retinopathy were not included because these patients do not require OCT examination.
Additionally, patients with untreated PDR were not included. It is possible that the laser
therapy could thin the choroid. Further investigation could examine patients with diabetic
retinopathy and compare with CT measured by spectral-domain OCT to correlate the
choroidal blood flow and CT.
In conclusion, diabetic choroidal angiopathy is related to the degree of severity of
retinopathy and presence of macular edema because of a significant decrease in the CT in
patients with diabetic macular edema or treated PDR. Spectral-domain OCT is a noninvasive
technology to assess the choroid and may be a useful tool in the evaluation of chorioretinal
vascular changes in diabetic retinopathy.
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Fig. 1.
Graph of mean CT in normal subjects and diabetic patients. Mean CT at each of the 11
locations measured at 500-μm (0.5 mm) intervals temporal (T) and nasal (N). P value
represents the result of statistical analyses (analysis of variance).
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Fig. 2.
Representative scans with CT measurements on Cirrus HD-OCT high-definition 1-line
raster scans. Perpendicular lines were drawn from posterior edge of RPE to choroid/sclera
junction using Cirrus HD-OCT software. Choroidal thickness was measured in the fovea and
at 500-μm intervals nasal and temporal to the fovea with the measurements expressed as
micrometers (red lines). Note that the choroid is thickest at center, thinner temporally, and
thinnest nasally. A. Representative scan from a normal subject; (B) representative scan from
a patient with mild non-proliferative diabetic retinopathy; (C) representative scan from a
patient with moderate nonproliferative diabetic retinopathy and diabetic macular edema; (D)
representative scan from a patient with treated proliferative diabetic retinopathy, note that
there is a disruption in the photoreceptor inner/outer segment junction probably because of
the retinal ischemia.
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Fig. 3.
Graph of mean subfoveal CT in normal subjects and diabetic patients. P values represent the
results of posttest comparison with Tukey multiple test.
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Table 1
Characteristics of Normal Subjects and Diabetic Patients
Normal NPDR DME PDR
Number (male/female) 24 (14/10) 11 (5/6) 18 (10/8) 20 (12/8)
Age 62 (11.7) 68.5 (9.6) 70.1 (10.7) 62 (9.8)
Use of insulin NA 3 (27%) 8 (44%) 11 (55%)
Arterial hypertension NA 8 (72%) 15 (83%) 16 (80%)
NA, not applicable.
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